Weld Capital Management’s Myriad Genetics MYGN Stock Holding History

Weld Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,876	Closed	-$213K	–	578
2020 Q1	$213K	Buy	+14,876	New	+$314K	0.11%	299
2019 Q1	–	Sell	-21,123	Closed	-$614K	–	800
2018 Q4	$614K	Buy	+21,123	New	+$760K	0.14%	282

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Weld Capital Management's MYGN Position: Q2 2020 in Review

Weld Capital Management sold out of Myriad Genetics (MYGN) in Q2 2020, closing a stake of 14,876 shares — an estimated $213K sold.

Weld Capital Management first reported a position in MYGN in Q4 2018 and held it in 2 quarters. The position peaked at $614K in Q4 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2020.

Weld Capital Management reported no remaining Myriad Genetics position as of Q2 2020 after selling out during the quarter.
Weld Capital Management sold 14,876 Myriad Genetics shares in Q2 2020, an estimated $213K.
Weld Capital Management first reported a position in Myriad Genetics in Q4 2018 and held it in 2 quarters.
Weld Capital Management's Myriad Genetics position peaked at $614K in Q4 2018.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2020.

Based on Weld Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.